| 5XKM: reference: Discovery of an Orally Bioavailable, Brain-Penetrating, In Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders., Mikami S, Sasaki S, Asano Y, Ujikawa O, Fukumoto S, Nakashima K, Oki H, Kamiguchi N, Imada H, Iwashita H, Taniguchi T, J Med Chem. 2017 Jul 31. doi: 10.1021/acs.jmedchem.7b00709. PMID: 28759228 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).